Stockscreener 앱 받기
73.00
3.58%
2.52
시간 외 거래:
72.98
-0.02
-0.03%
Astrazeneca PLC 주식(AZN)의 최신 뉴스
AstraZeneca’s Promising Phase 3 Study on CLL Treatment: Acalabrutinib vs. Standard Therapy - TipRanks
Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva, and Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports - GlobeNewswire Inc.
Is AstraZeneca PLC Depositary Receipt a good long term investmentFree Bull & Bear Market Updates - Autocar Professional
AstraZeneca’s Phase III Breast Cancer Study: A Potential Game-Changer? - TipRanks
Eli Lilly and AstraZeneca’s Promising Phase 3 Trial for KRAS G12C-Mutant NSCLC - TipRanks
AstraZeneca’s Osimertinib Study: Key Insights for Investors - TipRanks
AstraZeneca’s Latest Study: Assessing Ophthalmic Safety in Breast Cancer Patients - TipRanks
AstraZeneca’s NT-175 Study: A Promising Step in Cancer Treatment - TipRanks
AstraZeneca’s AZD4144 Study Completion: Market Implications and Insights - TipRanks
AstraZeneca’s Phase III Study on AZD0780: A Potential Game-Changer in Cardiovascular Treatment - TipRanks
AstraZeneca’s TROPION-LUNG01 Study: A Potential Game-Changer in NSCLC Treatment - TipRanks
AstraZeneca’s Promising Phase 1 Study on AZD0486 for B-Cell Non-Hodgkin Lymphoma - TipRanks
AstraZeneca’s Volrustomig Study: A Potential Game-Changer in Cancer Treatment - TipRanks
AstraZeneca’s New Prostate Cancer Study: A Potential Game Changer? - TipRanks
AstraZeneca’s Promising Phase III Study on NSCLC Treatment Advances - TipRanks
AstraZeneca’s Promising Phase 2a Asthma Study: Key Insights for Investors - TipRanks
AstraZeneca’s RACE-2L Study: Insights into NSCLC Treatment Outcomes - TipRanks
AstraZeneca to spend $50 billion in US production build out to avert tariff threat - Dallas News
AstraZeneca to Invest $50B Into US Pharmaceutical Expansion - Powder & Bulk Solids
What analysts say about AstraZeneca PLC Depositary Receipt stockFree Wealth Planning Blueprint - Autocar Professional
AstraZeneca PLC (AZN)’s Datroway Wins FDA Nod for Lung Cancer Breakthrough - MSN
AstraZeneca shares rise 2.44% premarket after announcing a $50 billion investment in US manufacturing and R&D. - AInvest
What drives AstraZeneca PLC Depositary Receipt stock priceAccelerated capital growth - jammulinksnews.com
AstraZeneca vows to spend US$50bil on US manufacturing boost - thestar.com.my
AstraZeneca Pledges Big Investment In US Manufacturing Amid Tariff Threats - insights.citeline.com
AstraZeneca commits $50 billion to US pharmaceutical manufacturing and R&D - BioProcess International
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US - Benzinga
AstraZeneca to invest $50 bn in the US as tariff threat looms - Yahoo.co
AstraZeneca to invest $50B in US to boost drug manufacturing and R&D - Proactive financial news
AstraZeneca’s Phase 2 Study on Trastuzumab Deruxtecan: A Potential Game-Changer in Cancer Treatment - TipRanks
AstraZeneca’s CORSAR Study: Unveiling Severe Asthma Insights in Russia - The Globe and Mail
AstraZeneca’s New Trial: A Step Forward in Liver Fibrosis Treatment? - TipRanks
Fear of tariffs? AstraZeneca calls $50 billion US investment a ‘deliberate choice’ - Euractiv
AstraZeneca’s Tozorakimab Study: A Potential Game-Changer in COPD Treatment - TipRanks
AstraZeneca’s Tezepelumab Study: Potential Breakthrough in Asthma Treatment - TipRanks
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures - TradingView
AstraZeneca picks Virginia for multibillion-dollar manufacturing site - Richmond Times-Dispatch
Lockheed Martin, AstraZeneca, DR Horton: Trending Tickers - Yahoo Finance
Astrazeneca, Phillip Morris & D.R. Horton earnings: Trending Tickers - Yahoo.co
AstraZeneca considers moving listing to US, the Times reports - Yahoo.co
AstraZeneca announces $50 billion US investment in manufacturing and R&D By Investing.com - Investing.com Australia
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D July 22, 2025 - James Sharp & Co.
AZN to invest $50bn in US, targets $80bn revenue by 2030 | AZN SEC FilingForm 6-K - Stock Titan
Global pharma companies do record deals with Chinese biotechs - Financial Times
Trending tickers: AstraZeneca, Verizon, Opendoor, Trump Media and Lindt & Spruengli - Yahoo.co
AstraZeneca unveils $50 billion US investment as pharma tariff threat looms - Reuters
Astra Pledges $50 Billion on US Manufacturing, Development - Bloomberg
AstraZeneca announces $50bn US investment in manufacturing and R&D - Proactive financial news
AstraZeneca unveils plans for £37bn investment in US amid tariff threats - Yahoo.co
AstraZeneca to invest $50bn in the US amid fears it could quit Britain - The Telegraph
AstraZeneca pledges $50bn in US investment as Trump pharma tariffs loom - Financial Times
AstraZeneca Vows to Spend $50 Billion on US Manufacturing, Development - MSN
AstraZeneca to invest $50bn in US after Trump tariff threat - The Times
Astrazeneca plots huge $50bn US investment after ditching UK expansion plans - Yahoo.co
AstraZeneca says to invest $50 bn in the US - Yahoo.co
AstraZeneca To Invest $50bn In The US, New Virginia Manufacturing Site Planned - DirectorsTalk Interviews
AstraZeneca To Invest $50 Bln In U.S. By 2030 To Boost Medicine Production And Research - Nasdaq
AstraZeneca vows to spend $50 billion on US manufacturing, development - CNBC TV18
AstraZeneca grows US presence with $50B in spending plans - BioPharma Dive
AstraZeneca pledges $50 bln investment in US as pharma tariffs loom By Investing.com - Investing.com
AstraZeneca to invest $50B in US economy by 2030 - AOL.com
AstraZeneca to invest $50B in US by 2030 - breakingthenews.net
AstraZeneca to spend $50-billion to expand manufacturing, research capabilities in U.S. - The Globe and Mail
자본화:
|
볼륨(24시간):